Thank you, Madam Chair, and thank you to all of the witnesses for being here today.
I'd like to go to Mr. Sorenson from Providence Therapeutics first.
Many people would be shocked to hear that as a Canadian company, you've received serious inquiries from other countries for vaccine procurement, but not from within Canada, with the exception of Manitoba.
You had mentioned that you're interested in not only producing mRNA vaccines for Canada but also in exporting them, including to developing countries in need. You mentioned in your testimony the company Genevant, which you said “is being infringed upon and not protected.”
Can you explain what you meant by that?